News about Clinical Trials

Bayer and Kumquat Biosciences Initiate Phase-I Study with KRAS G12D Inhibitor in Patients with KRAS-Mutated Tumors

Bayer and Kumquat Biosciences have begun a Phase-I trial of their KRAS G12D inhibitor targeting KRAS-mutated tumors, further bolstering Bayer’s precision oncology pipeline across pancreatic, colorectal, and lung cancers.

Clinical Trials | 11/10/2025 | By Dineshwori |  725

Sanofi and Partners Report Positive Phase 2 Results for AlphaMedix in Advanced GEP-NETs

AlphaMedix, which is developed by Orano Med and RadioMedix and now licensed to Sanofi, achieved all primary efficacy endpoints in the phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumours.

Clinical Trials | 08/10/2025 | By Dineshwori |  478

UK Halves Clinical Trial Approval Times Through Major Digital Reforms

Backed by major reforms and new digital platforms at the Medicines and Healthcare products Regulatory Agency (MHRA), the UK has reduced the average clinical trial approval time by more than half — from 91 days to just 41 days.

Clinical Trials | 08/10/2025 | By Dineshwori |  267

WHO launches Global Clinical Trials Forum

The Forum responds to World Health Assembly resolution WHA75.8, which called on WHO to improve the quality and coordination of clinical trials to generate high-quality evidence for health decision-making.

Clinical Trials | 08/10/2025 | By Dineshwori |  200

Merck Expands Tulisokibart Phase-2(b) Trials Across Three Inflammatory Diseases

Tulisokibart is an investigational anti-TL1A monoclonal antibody currently in Phase-3 trials for Ulcerative Colitis and Crohn’s disease, to be studied in hidradenitis suppurativa, radiographic axial spondyloarthritis and Rheumatoid Arthritis.

Clinical Trials | 07/10/2025 | By Dineshwori |  482

Onco3R Therapeutics Advances Phase 1 Trial of Novel SIK3 Inhibitor Targeting Autoimmune Diseases

Pierre Raboisson, CEO and Founder of Onco3R Therapeutics, said that the final results of the Phase 1 trial of O3R-5671 are expected in the first half of 2026.

Clinical Trials | 06/10/2025 | By Dineshwori |  271

WHO Warns of Insufficient Pipeline of Treatments and Diagnostics to Combat Antimicrobial Resistance

The World Health Organization (WHO) has raised the alarm over the shrinking pipeline of new antibacterials and diagnostics, urging greater investment in R&D to tackle the growing threat of antimicrobial resistance (AMR).

Clinical Trials | 03/10/2025 | By Dineshwori |  449

Roche Reports Positive Results from Phase III evERA Breast Cancer Study

Roche has announced positive results from the phase III evERA study evaluating its investigational oral selective oestrogen receptor degrader (SERD), giredestrant, in combination with everolimus in people with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer.

Clinical Trials | 24/09/2025 | By Dineshwori |  174

Ionis Experimental Drug Zilganersen Shows Promise in Trial for Alexander Disease

Ionis Pharmaceuticals has reported positive topline results from a pivotal study of its experimental drug zilganersen in patients with Alexander disease, a rare, progressive and often fatal neurological disorder.

Clinical Trials | 23/09/2025 | By Darshana |  290

Qiagen and APAGE Set Regional Consensus on Rapid Molecular Testing for Gastrointestinal Infections

The two-day meeting, held on 20–21 September in collaboration with the Asia-Pacific Association of Gastroenterology (APAGE), convened key opinion leaders from Singapore, Malaysia, Thailand, Indonesia, the Philippines and Australia.

Clinical Trials | 23/09/2025 | By Darshana |  181